Biotechnology company, Amgen, will buy Biovex Group for $425 million, Bloomberg reports. Thousand Oaks-based Amgen will pay $425 million in cash, plus up to $575 million more if BioVex hits some regulatory and sales milestones. The deal, which has been approved by the boards of directors of both companies, will close in the first quarter of this year. BioVex will become a wholly owned Amgen subsidiary, adds Business Journal.
Click here for the story from Bloomberg.
Click here for additional coverage from Business Journal.